Mutant <i>KRAS</i> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
Ruth Perets(Technion – Israel Institute of Technology), Dov Hershkovitz(Tel Aviv Sourasky Medical Center), Edmond Sabo(Carmel Medical Center), Valeria Semenisty, Ofer Ben‐Izhak(Rambam Health Care Campus), Ron Epelbaum(University of Bern), Talia Shentzer, Shada Sarji(Rambam Health Care Campus), Orli Greenberg(Tel Aviv Sourasky Medical Center), Tova Bick(Rambam Health Care Campus)
Cited by 96
Related Papers
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381